SCHEMBL13086150

SCHEMBL13086150

CN(C)CCNC(=O)c1ccc(-c2ccc(CN3C[C@@H](c4ccccc4)OC3=O)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 3/20 0.50
GRM2 Q14416 4/20 0.47
HPGD P15428 3/20 0.44
FADS1 O60427 1/20 0.44
MAPT P10636 2/20 0.43
THRB P10828 1/20 0.43
TP53 P04637 2/20 0.42
SETD7 Q8WTS6 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALOX5 P09917 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
PRSS12 P56730 1/20 0.41
MCHR1 Q99705 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8235890 1.00 CHRM4 (0.50) CHRM4GRM2HPGDFADS1MAPT
SCHEMBL8235202 0.92 GRM2 (0.46) CHRM4GRM2HPGDFADS1KDM4E
SCHEMBL13086151 0.92 GRM2 (0.46) CHRM4GRM2HPGDFADS1KDM4E
SCHEMBL2900422 0.85 CAMK2D (0.44) CHRM4HPGDFADS1TP53KDM4E
SCHEMBL8234135 0.85 GRM2 (0.47) GRM2PRSS12
SCHEMBL8237810 0.85 GRM2 (0.47) GRM2PRSS12
SCHEMBL2901567 0.85 GRM2 (0.47) GRM2PRSS12
SCHEMBL2943578 0.84 KDM4E (0.49) GRM2HPGDFADS1KDM4EALDH1A1
SCHEMBL13086254 0.84 KDM4E (0.49) GRM2HPGDFADS1KDM4EALDH1A1
SCHEMBL2894075 0.84 KDM4E (0.49) GRM2HPGDFADS1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816354-B2 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2010-10-19 US disclosed
US-7816354-B2 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2010-10-19 US disclosed
US-20090012089-A1 Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-01-08 US disclosed
US-20090012089-A1 Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-01-08 US disclosed
US-20070275966-A1 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators NPS PHARMACEUTICALS, INC. (US) 2007-11-29 US disclosed
US-20070275966-A1 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators NPS PHARMACEUTICALS, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275966-A1 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM2 CHRM4 108/4885GRM2 3/4885HPGD 1131/4885
US-20090012089-A1 Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators GRM1, GRIN1, GRM2 CHRM4 108/4885GRM2 3/4885HPGD 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.